Logo do repositório
 
Publicação

Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials

2018-10-10Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorAmbros, I.M.
dc.contributor.authorTonini, G.P.
dc.contributor.authorGross, N.
dc.contributor.authorMosseri, V.
dc.contributor.authorPötschger, U.
dc.contributor.authorBeiske, K.
dc.contributor.authorBerbegall, A.P.
dc.contributor.authorBénard, J.
dc.contributor.authorBown, N.
dc.contributor.authorCaron, H.
dc.contributor.authorCombaret, V.
dc.contributor.authorCouturier, J.
dc.contributor.authorDefferrari, R.
dc.contributor.authorDelattre, O.
dc.contributor.authorJeison, M.
dc.contributor.authorKogner, P.
dc.contributor.authorLunec, J.
dc.contributor.authorMarques, B.
dc.contributor.authorMartinsson, T.
dc.contributor.authorMazzocco, K.
dc.contributor.authorNoguera, R.
dc.contributor.authorSchleiermacher, G.
dc.contributor.authorValent, A.
dc.contributor.authorVan Roy, N.
dc.contributor.authorVillamon, E.
dc.contributor.authorJanousek, D.
dc.contributor.authorPribill, I.
dc.contributor.authorGlogova, E.
dc.contributor.authorAttiyeh, E.F.
dc.contributor.authorHogarty, M.D.
dc.contributor.authorMonclair, T.
dc.contributor.authorHolmes, K.
dc.contributor.authorValteau-Couanet, D.
dc.contributor.authorPearson ADJ, A.D.J.
dc.contributor.authorCastel, V.
dc.contributor.authorTweddle, D.A.
dc.contributor.authorPark, J.R.
dc.contributor.authorCohn, S.
dc.contributor.authorLadenstein, R.
dc.contributor.authorBeck-Popovic, M.
dc.contributor.authorDe Bernardi, B.
dc.contributor.authorMichon, J.
dc.contributor.authorAmbros, P.F.
dc.date.accessioned2019-02-19T16:27:56Z
dc.date.available2019-02-19T16:27:56Z
dc.date.issued2018-10-10
dc.description.abstractBACKGROUND: Biology based treatment reduction, i.e. surgery alone also in case of not totally resected tumors, was advised in neuroblastoma patients with localized resectable disease without MYCN amplification. However, whether the genomic background of these tumors may influence outcome was unknown and therefore scrutinized in a meta-analysis comprising two prospective therapy studies and a ‘validation’ cohort. PATIENTS AND METHODS: Diagnostic samples were derived from 406 INSS stages 1/2A/2B tumors from three cohorts: LNESGI/II and COG. Genomic data were analyzed in two age groups (cut-off: 18 months) and quality controlled by the SIOPEN Biology Group. RESULTS: In both patient age groups stage 2 tumors led to similarly reduced event-free survival (5y-EFS: 83+3% versus 80+4%), but overall survival was only decreased in patients >18m (5y-OS: 97+1% versus 87+4%; p=0.001). In the latter age subgroup, only tumors with SCA led to relapses, with 11q loss as the strongest marker (5y-EFS: 40+15% versus 89+5%; p<0,001). Below 18m, EFS but not OS was decreased only in case of 1p loss (5y-EFS: 62+13% versus 85+3%; p=0,041). SCAs were associated with worse OS only in patients >18m but not <18m. CONCLUSION: The tumor genomic make-up of resectable non-MYCN amplified stage 2 neuroblastomas has a distinct age-dependent prognostic impact in neuroblastoma patients. While in the younger age group tumors with unfavourable (SCA) and favorable genetics showed relapses, both without worsening OS, in the older age group only tumors with unfavorable genetics led to relapses and decreased OS.pt_PT
dc.description.versionN/Apt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/5899
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectNeuroblastomapt_PT
dc.subjectMYCNpt_PT
dc.subjectTumor Genomicspt_PT
dc.subjectDoenças Genéticaspt_PT
dc.titleAge-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trialspt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceJerusalém, Israelpt_PT
oaire.citation.titleSIOPEN – International Collaboration for Neuroblastoma Research, Annual General Meeting 2018 - 30-year anniversary Conference, 10 Oct 2018pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
LNESG-1-2-COG_30y CCRI.pdf
Tamanho:
316.75 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DGH - Posters/abstracts em congressos internacionais